Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Results of Phase III study into treatment for NSCLC

Vanita Noronha • 3 Jun 2019
ASCO 2019
Lung Cancer Gefitinib

Vanita Noronha, MBBS, MD, DM, of the Tata Memorial Center, Mumbai, India, discusses the results of a Phase III study investigating gefitinib versus combination therapy in the treatment of non-small cell lung cancer (NSCLC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Vanita Noronha

0:56
Lung Cancer: ASCO 2019 overview
Vanita Noronha • 3 Jun 2019
1:57
NSCLC treatment
Vanita Noronha • 2 Jun 2019

Related Videos

2:38
Phase I trial of binimetinib and pembrolizumab in NSCLC
Natasha Leighl • 17 Apr 2024
2:43
CHRYSALIS: amivantamab in wild-type, pre-treated NSCLC
Natasha Leighl • 17 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
The content of VJOncology is intended for healthcare professionals